Sequestering NGF by systemic administration of anti-NGF antibodies can alleviate, in part, pain-like behaviors in animal models of bone cancer and fracture-induced pain and also inflammatory pain of other tissue systems (82–88). Here, NGF is linked to bone neoplasm.